Research ArticleNeuropharmacology
Pharmacological Characterization of JNJ-40068782, a New Potent, Selective, and Systemically Active Positive Allosteric Modulator of the mGlu2 Receptor and Its Radioligand [3H]JNJ-40068782
Hilde Lavreysen, Xavier Langlois, Abdel Ahnaou, Wilhelmus Drinkenburg, Paula te Riele, Ilse Biesmans, Ilse Van der Linden, Luc Peeters, Anton Megens, Cindy Wintmolders, Jose Maria Cid, Andrés A. Trabanco, Jose Ignacio Andrés, Frank M. Dautzenberg, Robert Lütjens, Gregor Macdonald and John R. Atack
Journal of Pharmacology and Experimental Therapeutics September 2013, 346 (3) 514-527; DOI: https://doi.org/10.1124/jpet.113.204990
Hilde Lavreysen
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Xavier Langlois
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Abdel Ahnaou
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Wilhelmus Drinkenburg
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Paula te Riele
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Ilse Biesmans
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Ilse Van der Linden
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Luc Peeters
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Anton Megens
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Cindy Wintmolders
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Jose Maria Cid
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Andrés A. Trabanco
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Jose Ignacio Andrés
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Frank M. Dautzenberg
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Robert Lütjens
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Gregor Macdonald
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
John R. Atack
Janssen Research and Development, Beerse, Belgium (H.L., X.L., A.A., W.D., P.t.R., I.B., I.V.d.L., L.P., A.M., C.W., F.M.D., G.M., J.R.A.); Janssen Research and Development, Toledo, Spain (J.M.C., A.A.T., J.I.A.); and Addex Therapeutics, Geneva, Switzerland (R.L.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleNeuropharmacology
Pharmacological Characterization of JNJ-40068782, an mGlu2 Receptor PAM
Hilde Lavreysen, Xavier Langlois, Abdel Ahnaou, Wilhelmus Drinkenburg, Paula te Riele, Ilse Biesmans, Ilse Van der Linden, Luc Peeters, Anton Megens, Cindy Wintmolders, Jose Maria Cid, Andrés A. Trabanco, Jose Ignacio Andrés, Frank M. Dautzenberg, Robert Lütjens, Gregor Macdonald and John R. Atack
Journal of Pharmacology and Experimental Therapeutics September 1, 2013, 346 (3) 514-527; DOI: https://doi.org/10.1124/jpet.113.204990
Research ArticleNeuropharmacology
Pharmacological Characterization of JNJ-40068782, an mGlu2 Receptor PAM
Hilde Lavreysen, Xavier Langlois, Abdel Ahnaou, Wilhelmus Drinkenburg, Paula te Riele, Ilse Biesmans, Ilse Van der Linden, Luc Peeters, Anton Megens, Cindy Wintmolders, Jose Maria Cid, Andrés A. Trabanco, Jose Ignacio Andrés, Frank M. Dautzenberg, Robert Lütjens, Gregor Macdonald and John R. Atack
Journal of Pharmacology and Experimental Therapeutics September 1, 2013, 346 (3) 514-527; DOI: https://doi.org/10.1124/jpet.113.204990
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement